Cochrane Conflict of Interest Policy for Cochrane Library Content

Prepared by Fergus Macbeth, Angela Webster, Ruth Foxlee, Graham Smith, Kirsty Loudon, and Karla Soares-Weiser, with input from the COI Project Board.

<table>
<thead>
<tr>
<th>Effective date</th>
<th>Oct 14th 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Next review date</td>
<td>Date TBA</td>
</tr>
</tbody>
</table>

Trusted evidence.
Informed decisions.
Better health.
# Contents

1. **Introduction** 3
2. **Principles** 3
3. **Scope** 4
4. **Definitions** 4
5. **Funding and interests** 6
6. **Rules relating to declared interests** 9
7. **Responsibilities** 12
8. **Policy governance** 13
9. **Version history** 14
1 Introduction

Cochrane strives to attain the highest levels of objectivity and to ensure user confidence in the quality of Cochrane Library content. We recognize the importance of conflicts of interest and the way they can affect our relationships with healthcare consumers and the public, practitioners, policy makers and healthcare managers, researchers and research funders. The aims of this policy are to identify, prevent, or manage conflicts of interest. This policy is an update of the policy originally written in 2003 and revised in 2006 and 2014.

The policy applies to all those involved in the creation of Cochrane Library content, defined at the time of this policy revision as the Cochrane Database of Systematic Reviews (Cochrane Reviews, Cochrane protocols, editorials, commentaries and supplements) and Cochrane Clinical Answers. The policy was approved by the Cochrane Governing Board in February 2020 and it will apply prospectively from October 14, 2020 to all those involved in the production of new Cochrane Library content. The policy will be revised periodically.

2 Principles

Cochrane’s policy is based on the following principles:

Independence: Cochrane Library content should be independent, avoiding conflicts of interest associated with commercial sponsorship. It should also be produced by people or organizations that are free from such conflicts.

Freedom from interference: the process for conducting Cochrane Reviews, and the Cochrane groups and contributors responsible for producing Cochrane Library content, should be free from interference.

Assurance: users of the Cochrane Library should be assured that the content is produced in an independent manner.

Transparency: authors’ financial and non-financial interests, and their management, should be clear to users of the Cochrane Library.

Although Cochrane has adopted many of the International Committee of Medical Journal Editors (ICJME) recommendations on disclosing financial and non-financial relationships and activities, and conflicts of interest, this policy differs from that of many journals in the following ways:

- some types of financial sponsorship and support are forbidden;
- anyone involved in the creation of Cochrane Library content must disclose their relevant interests—both financial and non-financial—at the earliest opportunity in the editorial process: for Cochrane Reviews this is at protocol submission, or at review submission if the protocol was published elsewhere;
- the first and last authors must have no relevant financial conflicts, and at least two-thirds of the author team as a whole must be free of relevant financial conflicts.
3 Scope

This policy applies to all those engaged in producing content for the Cochrane Library (as defined in Section 4 below) including:

- Cochrane Review Group (CRG) editorial team members (paid and unpaid);
- authors of Cochrane Reviews and other Cochrane Library content;
- peer reviewers;
- Editorial staff employed by Cochrane;
- Cochrane Editorial Board.

4 Definitions

In relation to conflicts of interest the following definitions are relevant.

<table>
<thead>
<tr>
<th>Conflict of interest</th>
<th>A conflict of interest is defined as a set of conditions that pose a risk that professional judgement concerning a primary interest (such as patients' welfare or the validity of research) can be unduly influenced (consciously or unconsciously) by a secondary interest (such as financial gain).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cochrane Library content</td>
<td>Defined as the Cochrane Database of Systematic Reviews which includes Cochrane Reviews, Cochrane protocols, editorials, commentaries and supplements; and Cochrane Clinical Answers. The Cochrane Central Register of Controlled Trials (CENTRAL), federated search content, podcasts, translations of Cochrane content into other languages, and other knowledge translation products published in the Cochrane Library are specifically excluded from this definition.</td>
</tr>
<tr>
<td>Cochrane Review</td>
<td>The term ‘Cochrane Review’ refers to the published stages of a review, that is, the protocol, review, and any updates.</td>
</tr>
<tr>
<td>Cochrane Review Group editorial team members</td>
<td>Managing Editor, Assistant Managing Editor, Co-ordinating Editor, Deputy Co-ordinating Editor, Contact Editor, Statistical Editor/Statistician, Methods Editor, Information Specialist, Assistant Information Specialist and other methodologists (whether paid or unpaid).</td>
</tr>
<tr>
<td>Funder of a Cochrane Review</td>
<td>An organization which provides a grant, contract, or any form of financial support to one, several, or all authors, or funding that goes directly to their employer, home institution, or to the CRG, specifically for the purposes of undertaking a Cochrane Review.</td>
</tr>
<tr>
<td><strong>Industry-controlled clinical study</strong></td>
<td>Funding for the study is provided by a commercial organization. The commercial organization determines study design and methods (wholly or in part) and data analysis and reporting are controlled by that organization.</td>
</tr>
<tr>
<td><strong>Industry-supported clinical study</strong></td>
<td>A commercial organization provides some or all funding or material, non-financial support (e.g., placebo or active drugs, diagnostic or other test access) to the study, but independent researchers retain complete control over the study design, methods, data analysis and reporting.</td>
</tr>
<tr>
<td><strong>Commercial organization with a financial interest</strong></td>
<td>Any for-profit organization with a financial interest in the topic of Cochrane Library content. This definition is not intended to include government departments, not-for-profit medical insurance companies, health management or health research organizations, or independent patient advocacy groups.</td>
</tr>
<tr>
<td><strong>Not-for-profit organization</strong></td>
<td>An organization that operates as if it were a business but does not seek a profit. The primary focus is to pursue its objectives, and the money it raises is used to keep the organization operating. Examples include public universities, publicly funded health services, independent charities and non-governmental organizations such as the World Health Organization (WHO) but exclude those which are exclusively funded by a commercial healthcare organization that controls the funding (e.g. Foundation for a Smokefree World).</td>
</tr>
<tr>
<td><strong>Personal relationships</strong></td>
<td>Relationships with partner, spouse, immediate family member.</td>
</tr>
<tr>
<td><strong>Private practice</strong></td>
<td>A practice, outside the public healthcare system, in which a healthcare professional receives financial remuneration on a fee-for-service basis, rather than from a salary.</td>
</tr>
<tr>
<td><strong>Relevant</strong></td>
<td>In this policy financial interests are considered to be relevant if the payment comes from a commercial organization that manufactures (or is known to be developing), or distributes (anywhere in the world), an intervention or potential comparator. This applies even if the payment was made for work or advice that did not relate to the topic of the Cochrane Library content. In the case of Cochrane Reviews this applies regardless of the reported direction of effect. Non-financial interests are considered relevant if they have a direct and obvious connection to the topic of the review or other Cochrane Library content (see definition above).</td>
</tr>
</tbody>
</table>
Royalties

Income derived from the licensing or sale of healthcare-related goods or services. This may include income from books that promote an intervention, diagnostic test or prognostic marker that is relevant to the topic of the review or content of the article, electronic media (including apps), diagnostic and assessment tools, training programmes, and medical interventions and devices.

5 Funding and interests

5.1 Funding of Cochrane Library content

If the creation of Cochrane Library content is supported by direct external funding, the following rules apply.

- Cochrane Library content cannot be directly funded or produced by any commercial organization with a financial interest in the topic.

- Funders of Cochrane Library content should be declared in the ‘Sources of support’ section of the review or protocol, including a statement that the funder had no role in the design, conduct, or publication of the review (or update).

- Funders of Cochrane Reviews cannot interfere with review production, that is, the design, conduct, or publication of a review or its update.

- Funding may come from external non-commercial granting bodies such as governments and not-for-profit organizations (see Section 6.4).

5.2 Direct financial interests (payments to individuals)

Direct financial interests refer to payments made directly to an individual. Financial interests must be declared by all CRG editorial team members and by all authors (see Section 5.6) and peer reviewers (see Section 6.3) involved in creating Cochrane Library content. Cochrane Review Group editorial team members (paid and unpaid) must also declare any financial interests that relate to the Review Group’s topic areas (see Section 5.5). All financial support must be declared and there are no thresholds.

For clarity, the funding or financial support of interest here is that which comes from a commercial organization with a financial interest in the topic of a specific review (e.g., it is developing, manufacturing or distributing an intervention or competitor product that is the subject of the review) or, for CRG staff only, in the broader topic area of the CRG.

The following WILL prevent authorship of Cochrane Library content and are prohibited for CRG editorial team members (see Section 5.5 for timeframes).

- Current or past employment (part-time or full-time) (see Section 5.5 for timeframes) by a commercial organization with a financial interest in the topic of specific Cochrane Library content.
• Ownership of a commercial organization with a financial interest in the topic of specific Cochrane Library content.

• Personal ownership of (or pending application for) a patent for an intervention, diagnostic test or prognostic marker that is relevant to the topic of specific Cochrane Library content. This does not include patents developed, but not owned by individuals.

The following MAY prevent authorship of Cochrane Library content (see Section 5.5 for timeframes) and are PROHIBITED for CRG editorial team members. Whether these prevent authorship of Cochrane Library content depends on whether a person is first or last author and the overall proportion of authors in the team who have a conflict (see Section 6.1). This list is not intended to be exhaustive; if there is any doubt refer to the Research Integrity Editors and Conflict of Interest Panel (see Section 8.1).

• Payment from organizations with a financial interest related to the topic area of the Cochrane Library content for work carried out on their behalf, such as speaker fees, honoraria, consultancies, and membership of advisory boards.

• Support for sabbaticals and study tours from organizations with a financial interest related to the topic area of the Cochrane Library content.

• Payment of travel, accommodation, subsistence and conference registration expenses from organizations with a financial interest related to the topic area of the Cochrane Library content.

• Ownership of stock/shares in healthcare-related companies with a financial interest.

• Payment for legal testimony or advice from a commercial organization with a financial interest in a topic related to specific Cochrane Library content.

• Royalties relevant to the topic of the Cochrane Library content.

• Funding for research received from a commercial organization with a financial interest in the topic area of specific Cochrane Library content.

• Financial support for fellowships and other professional placements from organizations with a financial interest related to the topic area of the Cochrane Library content.

Income from relevant private professional practice should be declared but will not normally prevent contribution to the creation of Cochrane Library content. If there are concerns that the author derives significant income from one particular intervention relevant to the topic under investigation, this should be discussed with the Research Integrity Editors and Conflict of Interest Panel (see Section 8.1).

5.3 Indirect financial interests (payments to institutions)

An indirect financial interest exists when payments from a commercial organization with a financial interest (as described in Section 5.2) are made to an individual’s employer or home institution.

• All such payments must be declared.

• If the individual has any access to or control of the funds, or the payment has tangible, material benefit to their programme of research, this must be declared, and will be treated as explained in Section 5.2.
• If the individual has no access to or direct control of the funds, this should be declared, but does not constitute a conflict of interest.

5.4 Other (non-financial) relevant interests

Other, non-financial interests may result in a conflict of interest that could influence the development of Cochrane Library content. All those involved in the production of Cochrane Library content should think critically about how their perspectives, experiences, and positions have shaped their contribution to the development of the content. Transparency is key, however, declarations of non-financial interests **will not prevent participation** in the creation of Cochrane Library content.

The types of interests that should be considered, and declared, include, but are not limited to:

• publication in medical journals, the public press, broadcast and social media, of opinions relevant to the topic of the Cochrane Library content and interventions mentioned in the Cochrane Library content;

• work as a health professional or advisor on the topic or broader area relevant to the topic of the Cochrane Library content, whether in public or private practice;

• any affiliation to an organization (including not-for-profit) that has a declared ideological or political opinion relevant to topic of the Cochrane Library content.

5.5 Timeframes for declaration of interests

Individuals involved in the creation of Cochrane Library content must declare all relevant financial and non-financial interests that existed in the period beginning 36 months prior to the applicable date (see below) and ending at publication.

Authors in particular should be aware that any new relevant interests acquired during this timeframe must be declared immediately (see Section 7.1, “Responsibilities of authors”).

Specific start dates of the timeframe are as follows:

• For authors of Cochrane Reviews, 36 months prior to the date of protocol submission, OR 36 months prior to the date of review submission, if submitted directly with a prospective protocol registered elsewhere.

• For authors of a Cochrane Review update with no new protocol, 36 months prior to the date of update submission.

• For authors of all other types of Cochrane Library content, 36 months before work on the content started.

• For authors whose contribution started after article submission, 36 months prior to the date their involvement began.

• For peer reviewers, 36 months before the invitation to referee the review.

Cochrane group members and editorial staff employed by Cochrane are required to declare annually all relevant interests that existed in the previous 36 months.

5.6 Restrictions for authors of Cochrane Library content involved in clinical studies
Some additional restrictions are placed on people who have been involved in the conduct, analysis and publication of clinical studies.

- Anyone involved in writing a Cochrane Review, should declare whether they have had any direct involvement in the conduct, analysis, and publication of clinical studies (such as randomized clinical trials) that could be included in the specific review, and whether the study was industry-controlled or industry-supported (see Section 4, definitions). Direct involvement means named or other close involvement in the study design, conduct, analysis, or reporting. This would include chief investigators and members of advisory boards, but not usually members of independent data and safety monitoring committees or site investigators.

- Anyone engaged in writing a Cochrane Review, who has had direct involvement in the conduct, analysis, and publication of a study that could be included in the review cannot make study eligibility decisions about, extract data from, carry out the risk of bias assessment for, or perform GRADE assessments of that study.

- Cochrane Review authors who have had direct involvement in the design, conduct, analysis or publication of industry-controlled clinical studies that are eligible for inclusion in a review CANNOT be the first or last author of that Cochrane Review. An author’s direct involvement in industry-supported clinical studies that are relevant to the topic of a review does not prevent them from being first or last author of that Cochrane Review.

- Direct involvement of an author in the design, conduct, analysis and publication of industry-controlled clinical studies that are eligible for inclusion in the review also counts as a conflict when determining the overall proportion of authors on the team with permissible conflicts.

- For Overview Reviews, the following restrictions are placed on people who are authors of included reviews:
  - Anyone involved in writing a Cochrane Overview Review should declare whether they are an author of any of the reviews that could be included.
  - Anyone engaged in writing a Cochrane Overview Review who is an author of any review that could be included in the Overview Review cannot make eligibility decisions about, extract data from, or assess methodological quality/risk of bias for that review.

6 Rules relating to declared interests

6.1 Rules for authors of Cochrane Library content

When committing to produce Cochrane Library content, authors must complete a ‘Declaration of interest’ form at specific points in the editorial process. For authors of Cochrane Reviews, this must be done at protocol and review submission, annually thereafter, and just prior to protocol publication and review publication. For authors of Cochrane Review updates with no new protocol, this must be done at update submission, annually thereafter, and just prior to update publication.

The following rules apply to authors of Cochrane Library content (see Section 5.5. for timeframes):
• A person who is currently employed (part-time or full-time) or was employed (part-time or full-time) by a commercial organization with a financial interest in the topic **CANNOT** be an author of Cochrane Library content. See Section 5.5. for timeframes.

• A person who fully or partially owns an organization with a financial interest in the topic **CANNOT** be an author of any relevant Cochrane Library content.

• Someone who personally holds, or has applied for, a patent related to the topic **CANNOT** be an author of any relevant Cochrane Library content.

• Anyone engaged in writing a Cochrane Review, who has had direct involvement in the conduct, analysis, or publication of a study that could be included the review, is restricted in what they can do with those data: They **CANNOT** make study eligibility decisions about, extract data from, carry out the risk of bias assessment for, or perform GRADE assessments of that study.

• Where Cochrane Library content has multiple authors, at least 67% (two-thirds) of them should have no relevant financial conflicts (see Section 5.2).

• The first and last authors of Cochrane Library content must have no relevant financial conflicts (see Section 5.2). See Section 5.5 for timeframes.

• Authors joining the author team of a Cochrane Review after the publication of the protocol or after publication of the full review (for an update) must be free of relevant financial conflicts of interest for 36 months before joining the team.

• For Cochrane Review updates with no new protocol, the relevant time period is 36 months before the date of update submission, through to publication of the completed update.

• Declarations of non-financial interests **WILL NOT PREVENT** participation in the development of Cochrane Library content.

### 6.2 Rules for Cochrane Review Groups and editorial staff employed by Cochrane

The following restrictions apply to all CRG team members (paid and unpaid), Editorial Board members, and all editorial staff employed by Cochrane:

• No CRG is permitted to accept funding from any commercial organization with a financial interest in the CRG topic area.

• All editorial team members of CRGs (paid and unpaid), editorial staff employed by Cochrane, and members of the Editorial Board must have **NO** relevant financial conflicts of interest (see Section 5.2 and 5.3).

• Anyone newly appointed to a role in a CRG, as a member of editorial staff employed by Cochrane, or to the Editorial Board must be free of relevant financial conflicts of interest from the date of appointment.

• All CRG staff, including Co-ordinating Editors, editorial staff employed by Cochrane, and Editorial Board members in post at the time of this policy launch in October 14, 2020 who have financial conflicts of interest should not sign off reviews of topics relevant to those interests. If they remain in post, they should have divested themselves of those interests within five years from the date
the policy took effect October 2020, and should not acquire any new relevant financial conflicts of interest so that by October 2025 they will be free of such interests.

- Editors with conflicts of interest, who have not yet divested themselves of those interests, should not undertake peer review or be a contact editor or provide sign-off on Cochrane Reviews to which their conflicts relate.
- Editors are prohibited from being employees of commercial organizations with a financial interest in the CRG topic area.
- All editorial team members of CRGs (paid and unpaid), editorial staff employed by Cochrane, and Editorial Board members must complete the Declaration of interest form and update it annually (between January and March each year).

Cochrane Editors and editorial staff can author Cochrane Reviews, but must exclude themselves entirely from the editorial process for that review to ensure separation of the author and editorial processes. These tasks should be taken on by another Editor or member of the editorial team. Authors who hold editorial positions in Cochrane should declare these positions in their Declaration of interest forms for each review they author, and a statement that they were not involved in the editorial process for that review should be included in the ‘Declarations of Interest’ section of the Cochrane Review.

6.3 Rules for peer reviewers

Peer reviewers must complete a ‘Peer reviewer declaration of interest’ separately for each peer review of a Cochrane Review. They must do so before they undertake any work on a review and update their declarations if any conflicts of interest become apparent during review.

Peer reviewers must report any relationship with the authors of the Cochrane Review they are refereeing.

The following restrictions apply to anyone engaged in peer reviewing Cochrane Library content:

- Employees (full-time or part-time) of an organization with a financial interest in the topic of specific Cochrane Library content should not act as peer reviewers.
- Anyone who owns a commercial organization with a financial interest in the topic of the specific Cochrane Library content should not act as a peer reviewer.
- Anyone who personally owns a patent (or has a pending application) for an intervention, diagnostic test or prognostic marker that is relevant to the topic of the specific Cochrane Library content should not act as a peer reviewer. This does not include patents developed but not owned by an individual.
- Those with other direct financial interests (see Section 5.2) in an intervention or any comparators considered in the review should not usually act as peer reviewers.

It is the responsibility of the Editorial Team selecting peer reviewers (e.g. CRG or DTA Editorial Team) to decide whether the disclosed conflicting interests are sufficient to withdraw the participation of the peer reviewer and to invite an alternative peer reviewer. If the Editorial Team considers the conflict of interest to be minor and agrees that it is unlikely to affect the judgement of the peer reviewer, the Editorial Team
must disclose the potential conflict of interest to the review authors when sharing the peer reviewer’s comments. If the Editorial Team considers the conflict of interest to be major and agrees that it is possible that it will affect the judgement of the peer reviewer, the peer reviewer must be replaced.

6.4 Rules for not-for-profit organizations

Not-for-profit organizations that employ Cochrane authors, or fund reviews, may have a specific interest in the conclusions of a Cochrane Review. While they may or may not gain financially as a result of taking a specific position about a healthcare intervention, they may try to influence the conduct, conclusions or publication of that review. For example, a high-profile charity or foundation that has a well-documented position on a particular healthcare intervention may fund a Cochrane Review or provide substantive primary research funding in the topic area of the review. Although it is not possible to draft specific rules about this issue, the CRG should raise this issue with authors, and, if there appears to be a risk of undue influence, the matter should be discussed with the Research Integrity Editors and Conflict of Interest Panel (see Section 8.1) and the Editor in Chief as early as possible.

7 Responsibilities

7.1 Responsibilities of authors

- Authors of Cochrane Library content must provide an accurate and complete declaration of relevant financial and non-financial interests.

- Declarations must be made at the earliest opportunity in the editorial process. For Cochrane Reviews, this is at the time of protocol submission, or at review submission if the protocol was published elsewhere.

- The declarations provided by authors should be clear and detailed enough for readers to be able to understand the potential implications of what is being declared.

- Authors of Cochrane Library content must declare all relevant financial and non-financial interests at specific points in the editorial process. For authors of Cochrane Reviews, this must be done at protocol and review submission, annually thereafter, and just prior to protocol publication and review publication. For authors of Cochrane Review updates with no new protocol, this must be done at update submission, annually thereafter, and just prior to update publication. Authors must also declare all relevant interests before publication of an amendment to a review if the amendment requires a new citation version of the review to be published.

- In addition to the specific time points above, if an author acquires any new relevant interest at any stage while the Cochrane Library content is being prepared, this must be reported to the Cochrane editorial group immediately. The group will refer to the Research Integrity Editors and Conflict of Interest Panel where necessary.

7.2 Responsibilities of Cochrane Review Groups and editorial staff employed by Cochrane

- Once work on Cochrane Library content is underway, changes to the author line-up will not be permitted as a means of addressing a breach of this policy.

- Where there is concern about an author’s declared interest at any stage during the review authoring process, CRG editorial team members should manage issues in line with the policy
and, if necessary, should seek further advice from the Research Integrity Editors and Conflict of Interest Panel (see Section 8.1).

- The CRGs should check that peer reviewers’ declarations comply with the policy at the time they are invited to peer review and when they submit their reports.

- Central editorial staff should check and clarify all authors’ declarations comply with the policy for other Cochrane Library content (i.e., editorials, supplements and Cochrane Clinical Answers) at the time of commissioning, and before publication.

- Central editorial staff are responsible for checking that all members of the department comply with the policy.

- A designated member of the CRG is responsible for checking that all CRG members comply with the policy.

8 Policy governance

8.1 Conflict of Interest Panel

The Research Integrity Editors and the Conflict of Interest Panel provide guidance on conflicts of interest in the context of Cochrane Library content. They provide advice on implementation of the policy and arbitrate potential policy breaches. See further information about the Research Integrity Editors and Conflict of Interest Panel, including the terms of reference of the Conflict of Interest Panel.

The Conflict of Interest Panel reports to the Editor in Chief of the Cochrane Library.

Queries about the application of this policy can be referred to the Research Integrity Editors and Conflict of Interest Panel using the referral process. The Conflict of Interest Panel is supported by the Research Integrity Team who can be contacted via coiarbiter@cochrane.org.

8.2 Appeals

Appeals against the decisions of the Research Integrity Editors and Conflict of Interest Panel should be made via coiarbiter@cochrane.org. For cases managed by the Research Integrity Editor, appeals will go to the Senior Research Integrity Editor for a final decision. For cases managed by the Senior Research Integrity Editor, appeals will go to the Editor in Chief and Conflict of Interest Panel (the final decision lies with the EiC). For cases that were jointly managed by the Senior Research Integrity Editor and the Conflict of Interest Panel the Editor in Chief will make the final decision.

8.3 Non-adherence

Unpublished Cochrane Library content that is considered to be in breach of this policy will be referred to the Research Integrity Editors and Conflict of Interest Panel and may be rejected for publication, subject to appeal.

Published Cochrane Library content that is considered to be in breach of this policy will be referred to the Research Integrity Editors and Conflict of Interest Panel and may not be published or may be withdrawn from the Cochrane Library.

Wilful failure to disclose relevant conflicts of interest will be considered a form of scientific misconduct.

8.4 Policy audit
A full audit of Cochrane Library content to determine adherence to this policy will be carried out every three years by the Research Integrity Team in collaboration with the Conflict of Interest Panel. Partial audits and spot checks may be carried out at the discretion of the Editor in Chief.

A review of cases referred to the Research Integrity Editors and Conflict of Interest Panel and the results of the audits may be used to inform development of resources to support the implementation of the policy by those producing Cochrane Library content.

### 9 Version history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1</td>
<td>2003</td>
<td>First Commercial Sponsorship policy</td>
</tr>
<tr>
<td>Version 1.2</td>
<td>April 2004</td>
<td>Policy revised after a consultation process arising from a letter to the Cochrane Steering Group from several Cochrane contributors who felt that the existing policy ought to be more restrictive. The 2004 policy limited or prohibited commercial sponsorship of reviews, entities or activities.</td>
</tr>
<tr>
<td>Version 1.3</td>
<td>April 2005</td>
<td>Amended following consultation at 11th and 12th Annual General meetings and Cochrane Steering Group meetings.</td>
</tr>
<tr>
<td>Version 2</td>
<td>March 2014</td>
<td>Policy revised and reorganized into two parts after consultation: one for Cochrane Groups and individuals, and one for Cochrane Reviews.</td>
</tr>
<tr>
<td>Version 3</td>
<td>October 2020</td>
<td>This policy replaces Cochrane’s Commercial Sponsorship policy dated March 2014.</td>
</tr>
<tr>
<td>Version 3.1</td>
<td>January 2021</td>
<td>Minor edits to improve clarity of text plus two edits made with approval from the Editorial Board (section 5.2 updated to clarify that financial interests in the ‘broader topic area of the CRG’ applies only to CRG staff and section 6.3 to clarify that it is the responsibility of the Editorial Team selecting peer reviewers to decide whether the disclosed conflicting interests are sufficient to withdraw the participation of the peer reviewer).</td>
</tr>
<tr>
<td>Version 3.2</td>
<td>May 2021</td>
<td>Minor edits to improve clarify of text, including clarification on application of section 5.6 to authors of Cochrane Overview Reviews and clarification (section 6.3) that personal ownership of a patent or a commercial organization with an interest in the outcome of the Cochrane Library content prohibit being a peer reviewer.</td>
</tr>
<tr>
<td>Version 3.3</td>
<td>October 2021</td>
<td>Minor edits to improve clarity plus addition of points regarding Cochrane Editors who are authors of reviews (Section 6.2) and collection of Declarations of Interest for Amendments (Section 7.1).</td>
</tr>
<tr>
<td>Version 3.4</td>
<td>January 2022</td>
<td>Minor edits to reflect new terminology of departments within the Central Executive Team.</td>
</tr>
<tr>
<td>Version 3.5</td>
<td>August 2022</td>
<td>Minor edits to improve clarity in the definition of ‘Conflict of interest’ (Section 4) and in the requirement for declaring indirect financial interests (Section 5.3). Minor edits to reflect new terminology of departments within the Central Executive Team, to reflect Cochrane’s new process for submitting review proposals, and correct information on submitting referrals to the Research Integrity team.</td>
</tr>
<tr>
<td>Version 3.6</td>
<td>May 2023</td>
<td>Edits to Sections 2, 5.5, 6.1, 7.1 and 7.2 to reflect changes to Cochrane’s submission process for authors of Cochrane Reviews, protocols, and updates. These changes affect the point in time when authors must first submit their declarations of interest (at article submission), as well as the applicable timeframes for relevant financial and non-financial interests (beginning 36 months prior to article submission). Edits to improve clarity on the relevant interests that must be declared (Sections 2, 5.5, 7.1), and on changes to the author team (Section 7.2). Edits to Section 5.6 and 6.1 concerning authors involved in studies eligible for inclusion in Cochrane Reviews and Overview Reviews, to clarify the relevant type of involvement and the restrictions on affected authors.</td>
</tr>
</tbody>
</table>